COMMUNIQUÉS West-GlobeNewswire

X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson's Disease Therapy
23/06/2026
GAINESVILLE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- X-tosis Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Novel Parkinson's Disease Therapy. The ward supports advancement of X- [...]
Peptide Mind Launches Expanded Research Library and Educational Tools for Peptide Research Community
23/06/2026
New platform resources provide structured, citation-backed peptide education and research tools for students, researchers, and science-minded readers. Official logo of the Peptide Mind research and education platform. [...]
Berry Street and Tia Partner to Deliver Clinical Nutrition Therapy at Every Stage of a Woman's Life
23/06/2026
Tia members gain access to Berry Street's AI-powered platform and network of 1,800+ Registered Dietitians specializing in women's health NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Berry Street , the leading metabolic [...]
Lungpacer Medical Announces Presentation of DONATE Data Reporting an Increase in Availability of Donor Lungs
23/06/2026
Data presented at the American Transplant Congress 2026 reports transvenous phrenic nerve stimulation reduced lung collapse and significantly increased availability of lungs that meet transplant criteria versus [...]
SK pharmteco lance SKyvec™, une plateforme unifiée de vecteurs viraux à haut rendement destinée à accélérer le développement des thérapies géniques, de la fabrication au patient
23/06/2026
RANCHO CORDOVA, Californie, 23 juin 2026 (GLOBE NEWSWIRE) -- SK pharmteco annonce ce jour le lancement de SKyvec™, sa plateforme exclusive et multimodale de vecteurs viraux. Conçue pour soutenir les programmes de [...]
RESTEM to Present at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
23/06/2026
MIAMI, June 23, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that CEO, [...]
GENFIT : Données positives de Phase 1b obtenues avec GNS561 en combinaison, dans une population de patients atteints de cholangiocarcinome lourdement prétraités
23/06/2026
Le médicament expérimental GNS561 a démontré un profil de sécurité et de tolérabilité favorable dans une étude de Phase 1b évaluant son potentiel en combinaison avec un inhibiteur de MEK (MEKi) Étude menée dans une [...]
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
23/06/2026
Investigational drug GNS561 showed a favorable safety and tolerability profile in a Phase 1b study evaluating its potential in combination with a MEK inhibitor (MEKi) Study conducted in a heavily pretreated, high - [...]
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
23/06/2026
Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalking horse” bidders in [...]
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
23/06/2026
Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO Platform KUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group [...]
Ichnos Glenmark Innovation (IGI) Announces Appointment of Mariana Cota Stirner, M.D., Ph.D., as Chief Medical Officer
23/06/2026
Physician-Scientist with Proven Track Record of Global Drug Development and Regulatory Approvals to Lead Clinical Development of IGI’s Multispecific™ Oncology Pipeline NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Ichnos [...]
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
23/06/2026
Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin Company intends to file the Phase 3 protocol in Q3 2026 and is actively [...]
Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults
23/06/2026
U.S. Phase 2 trial met primary endpoints, with up to 11.5% weight loss at 36 weeks, showing continued weight reduction at a consistent rate and no evidence of a slowing trajectory CX11 demonstrated favorable GI [...]
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
23/06/2026
On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy [...]
CoreHealth Announces Leadership Transition as Charles Martin Appointed Chief Executive Officer
23/06/2026
TORONTO, June 23, 2026 (GLOBE NEWSWIRE) -- CoreHealth Technologies Inc. today announced that Michael Peters will conclude his tenure as Chief Executive Officer at the end of June, following five years of leadership that [...]
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
23/06/2026
REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
23/06/2026
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
23/06/2026
Data published in Molecular Genetics and Metabolism Reports suggest MIPLYFFA (arimoclomol) was well tolerated in pediatric patients with no new safety signals observed BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra [...]
Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors
23/06/2026
A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced-proximity therapeutics. Dr. Houston's deep experience with protein [...]

Pages